They are both mammals, they share some identical genes, but they should not share the same drug: ivermectin.
What is ivermectin? Ivermectin is an avermectin – a type of naturally occurring drug, by way of fermentation – discovered through culture of the fungus Streptomyces avermitilis in 1967. It is an effective anti-parasitic drug whose discoverers won the Nobel Prize in 2015.
Ivermectin has been and is currently used to treat humans and animals for pathogen infestation or infection, and is part of the World Health Organization’s (WHO’s) Model List of Essential Medicines. Ivermectin may stop diseases like onchocerciasis or river blindness, an illness caused by helminths that damage capillaries of the eye; lymphatic filariasis, with accumulation of Wucheria worms in lymph vessels or glands; and scabies, a skin irritation caused by Sarcoptes mites. It may be administered by tablet, ointment, or injection in appropriate concentrations.
In our crazy COVID-19 times, its use against viral infection has been tested in humans, and the drug is currently being utilized to treat COVID-positive patients in 24 developing countries, including India, Peru, and others.
“But SARS-CoV-2 is a virus, not a parasite, correct?” one might ask. “Why would one think a drug which affects growth of parasites could also inhibit growth of viruses?”
Viruses and parasites are different types of microbes. Viruses are considered non-living, as they require a host to reproduce. Parasites are classified in the same grouping as humans: eukaryotes. They may function alone, but thrive on nutrients and housing from a host. Both viruses and parasites may elicit a similar outcome from infection in the human body, namely clumping of blood cells, or microvascular occlusion.
The commonality of disease sequelae prompted investigators to question if ivermectin might prove useful for treatment of COVID-19 patients. The alteration in blood clotting may damage the lining, or endothelium, of capillaries. When damaged vessels surround the alveoli or functional units for gas exchange in lungs, victims are deprived of oxygen, hence the need for ventilators in severe COVID-19 cases.
As of July 2021, the National Institutes of Health (NIH) followed 16 of 55 studies for assessment of ivermectin’s effects on COVID-19 cases. It is thought that ivermectin interferes with one or more of 20 identified levels for infection, level one being binding virus to host cells (blocked by steric hindrance?), through host inflammatory responses, thus stopping viral progression.
Some studies have been discounted for small sample size, non-randomization of subjects, or incomplete follow-up. Dr. Omura, the ivermectin Nobel co-laureate, with colleagues, published a review with data showing a sizable decrease in morbidity and mortality for human COVID-19 patients treated with ivermectin.
Due to fervent wishes to stay safe, people have taken drugs intended for animal use. The Food and Drug Administration (FDA) recently tweeted, “you are not a horse. You are not a cow. C’mon ya’ll. Stop it.” The formulations and dosages for animal medications are NOT appropriate for humans. The ivermectin injection for cattle contains polyethylene glycol (PEG), a.k.a. antifreeze.
Ivermectin holds promise for SARS treatment: it has been approved, is inexpensive, and could be repurposed. But the best primary prevention for COVID-19 remains the Pfizer, Moderna, or J&J vaccine!
Programming Note: Listen to Julia Brodt report this story live today during Talk Ten Tuesdays, 10 Eastern.
I receive a lot of newsletters every morning to help me stay abreast of what is happening in the healthcare industry. A troubling recent trend
EDITOR’S NOTE Day 3 of the federal shutdown continues. This article by Mark Spivey is part of a special section today published by RACmonitor and
Please log in to your account to comment on this article.
Gain clarity and confidence in OB‑GYN coding with this expert‑led webcast featuring Stacey Shillito, CDIP, CPMA, CCS, CCS‑P, CPEDC, COPC. You’ll learn how to apply global maternity package rules accurately, select the right CPT codes for procedures and visits, and identify documentation gaps that lead to denials. With practical guidance and real examples, this session helps you strengthen compliance, reduce audit risk, and ensure accurate reimbursement for women’s health services.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s third quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
BLOOM INTO SAVINGS! Get 25% OFF during our spring sale through March 27. Use code SPRING26 at checkout to claim this offer.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
